Raymond James Financial
MBX

Raymond James Financial’s MBX Biosciences MBX Stock Holding History

Raymond James Financial’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-761
Closed -$8.68K – 6932
2025
Q2 		$8.68K Buy
+761
New +$7.75K ﹤0.01% 5975

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial's MBX Position: Q3 2025 in Review

Raymond James Financial sold out of MBX Biosciences (MBX) in Q3 2025, closing a stake of 761 shares — an estimated $8.68K sold.

Raymond James Financial first reported a position in MBX in Q2 2025 and held it in 1 quarter. The position peaked at $8.68K in Q2 2025. 118 funds tracked by Wall St. Rank hold MBX as of Q3 2025.

  • Raymond James Financial reported no remaining MBX Biosciences position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 761 MBX Biosciences shares in Q3 2025, an estimated $8.68K.
  • Raymond James Financial first reported a position in MBX Biosciences in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's MBX Biosciences position peaked at $8.68K in Q2 2025.
  • 118 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.